Another poker in the fire!
CTD Holdings Announces FDA Authorization to Proceed with Single Patient IND for Use of Trappsol(R) Cyclo(TM) to Treat Alzheimer's Disease
ALACHUA, FL -- (Marketwired) -- 03/12/18 -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that a single patient IND expanded access program using the company's proprietary formulation of hydroxypropyl beta cyclodextrin, Trappsol® Cyclo™, for the treatment of Alzheimer's Disease has been authorized to proceed by US FDA. The IND was submitted by Diana Kerwin, MD, of the Kerwin Research Center, LLC. Dr. Kerwin is a recognized expert in Alzheimer's disease and memory disorders who was previously part of the Northwestern University, National Institute on Aging-funded, Cognitive Neurology and Alzheimer's Disease Center, where she oversaw clinical trials and clinical research for the development of treatments for Alzheimer's Disease. As part of the IND application, CTD provided Dr. Kerwin with access to its Type II Drug Master File at the FDA and provided technical input on development of the protocol. CTD will play an active role in monitoring progress of the program.
"With few treatment options available for Alzheimer's disease, there is an enormous unmet medical need for new approaches to tackle this devastating disease," said N. Scott Fine, CTD's Chairman and CEO. "When we were requested to provide Trappsol® Cyclo™ for this compassionate use program, we agreed, with the hope that it would help not only this single individual but ultimately many more who suffer from this devastating disease."
